Brookline Capital Management Weighs in on QNCX Q3 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Research analysts at Brookline Capital Management lowered their Q3 2025 earnings per share estimates for shares of Quince Therapeutics in a research note issued to investors on Wednesday, July 16th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($0.25) for the quarter, down from their previous estimate of ($0.24). The consensus estimate for Quince Therapeutics' current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics' Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.51) EPS and FY2029 earnings at $0.48 EPS.

Other equities analysts have also recently issued reports about the company. D. Boral Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Quince Therapeutics in a report on Thursday, July 17th. Wall Street Zen cut Quince Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $8.00.

Quince Therapeutics Stock Performance

NASDAQ:QNCX remained flat at $1.86 during mid-day trading on Monday. The company had a trading volume of 197,740 shares, compared to its average volume of 232,774. The stock has a market cap of $84.57 million, a PE ratio of -1.34 and a beta of 0.96. The stock's fifty day moving average price is $1.40 and its 200-day moving average price is $1.37. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.05 and a quick ratio of 4.05. Quince Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.45.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10).

Hedge Funds Weigh In On Quince Therapeutics

A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in Quince Therapeutics during the 4th quarter worth $55,000. Two Sigma Investments LP bought a new stake in Quince Therapeutics during the 4th quarter worth $57,000. Northern Trust Corp grew its position in Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after acquiring an additional 16,501 shares during the last quarter. Intellectus Partners LLC bought a new stake in Quince Therapeutics during the 1st quarter worth $71,000. Finally, Shay Capital LLC grew its position in Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after acquiring an additional 104,616 shares during the last quarter. Institutional investors and hedge funds own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.